Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The company
sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/12/2018 according to
Article 30 of the Listing Rules.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : Release from
the company stating that it will begin distributing the products of the company "Alcon" during the first quarter of
2019.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The company
sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 30/09/2018, according
to Article 30 of the Listing Rules.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The company
sent a release regarding the news published on one of the websites titled "The arrest of the Managing Director of
Ibn Sina Pharma due to the issue of drug monopoly".

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : EGX decided to
suspend trading on the company effective 01/10/2018 till the company responds to EGX inquiries concerning what was
published on one of the websites.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : Reference to
what was published on 20/06/2018, the company sent a release from stating that the lawsuit was adjourned to
18/09/2018.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The company
sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 30/06/2018 according to
Article 30 of the Listing Rules.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : Release from the
company denying the existence of any contractual relations or association with Abraaj Capital Group

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The Listing
Committee held on 06/06/2018 decided to address the company to abide by the provision of Article 31 of the Listing
Rules and 45 of the Executive Regulations.

The
listing committee held on 17-04-2018 has approved to list the company's capital
increase from EGP 168 Million to EGP 180.5 Million , such capital increase amounted to EGP
12.5 Million distributed over 50 Million shares at par
value of EGP 0.25 per share paid in cash
.
These
new shares will be added to Egx database starting 24/04/2018 trading session.
The
company is committed to lock-up all shares of this capital increase that
amounted to 50,000,000 shares to fulfill terms of its share lock-up as set in
the placement prospectus of the company's shares , in accordance with the item
no. (7) of the article no. (7) of the listing rules, provided that the lock-up
period shall be completed for "eighteen months from
the date of trading its shares in the Egyptian Exchange" according to
the letter received from MCDR on 16\04\2018.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The company
sent its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/03/2018 according to
Article 30 of the Listing Rules.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : Release from the
company concerning the completion of the commercial register and the release of the proceeds of the capital
increase of 290 million pounds

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : The Board of
Directors' meeting minutes held on 04/03/2018 concerning the unaudited financial results for the period ended
31/12/2017.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : Referring to
the announcement published on the trading screens regarding the latest developments of case no. 2952 for the year
2015, the economic census and number 1898 for the year 2016 economic misdemeanors and clarification from the
company note that the company appealed the ruling before the competent authorities and was set on Saturday,
19/05/2018 in front of Second Circuit Resume.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent : Release from
the company concerning the latest developments of the case No. 2952 for the year 2015 inventory commercial
restricted number 1898 to 2016 commercial misdemeanors.

Company Name : Ibnsina PharmaISIN Code : EGS512O1C012Reuters Code : ISPH.CAContent :The company sent
its Disclosure Form for the BoD & the shareholders' structure for the period ended 31/12/2017 according to
Article 30 of the Listing Rules.

The Listing Committee held on 08/11/2017 has approved to list the shares of Ibnsina Pharma (initially listing) The company’s issued capital is EGP 168 Million, distributed over 672 million shares at a par value of LE 0.25 per share, to be listed in the Egyptian Securities Board- Stocks.According to the Listing Rules set by EFSA board of directors’ resolution